This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

24 Mar 2020

Positive update on the development of new XF‐platform drug formulations

Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections.

Destiny Pharma, a clinical-stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), has completed the initial phase of its project to develop new topical formulations of the former’s novel XF‐platform drugs.

Further to forming the collaboration with MedPharm — a contract provider of topical and transdermal product design and formulation development services — last year, the project has identified a range of new, stable XF formulations with promising drug release profiles and scope for delivery of XF drugs (including clinical stage XF-73, XF-70 and DPD-207 compounds) designed to treat dermal and ocular infections.

These formulations will form the basis of XF drug delivery for Destiny Pharma’s preclinical and clinical programmes and treatments for both acute and chronic infections.

Selected formulations will also be incorporated into ongoing grant-funded projects including Destiny Pharma's UK-China AMR, Innovate UK grant-funded collaboration.

"There is an unmet medical need for novel anti-infectives that address dermal and ocular infections with a significantly reduced potential for generating antimicrobial resistance. Our lead drug candidate from the XF-platform, XF‐73 nasal gel, for the prevention of post‐surgical infections, is currently in Phase IIb development with data expected in mid-2020,” said Neil Clark, CEO of Destiny Pharma.

Related News